Oncology Today with Dr Neil Love: Novel Investigational Antibody-Drug Conjugates for Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate directed against _____.**
   a. FRα
   b. CDH6
   c. HER2
   d. XPO1

2. **What was the approximate objective response rate with R-DXd for patients with platinum-resistant advanced ovarian cancer (OC) across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?**
   a. 15%
   b. 25%
   c. 50%
   d. 85%

3. **Which of the following adverse events is most commonly associated with R-DXd?**
   a. Headache
   b. Pneumonitis
   c. Rash
   d. Nausea

4. **What was the approximate incidence of any-grade interstitial lung disease among patients receiving the 5.6-mg/kg dose of R-DXd in the REJOICE-Ovarian01 study?**
   a. 0%
   b. 1%
   c. 3%
   d. 6%
   e. 10%

5. **Which of the following statements is true regarding tumor responses and CDH6 expression levels in patients receiving R-DXd in the REJOICE-Ovarian01 study?**
   a. Tumor responses were observed in only those patients with high CDH6 expression levels and with only the highest dose of R-DXd
   b. Tumor responses were observed in only those patients with high CDH6 expression levels but across all dose levels
   c. Tumor responses were observed in patients across various CDH6 expression levels but only with the highest dose of R-DXd
   d. Tumor responses were observed in patients across various CDH6 expression levels and across all dose levels
   e. CDH6 expression levels were not analyzed in the REJOICE-Ovarian01 study